Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

5076 Pages (Click to Jump) V  « < 303 304 305 306 307 308 309 > »    
Reply to this topic

post Posted: Nov 14 2019, 10:44 AM
  Quote Post

Posts: 1,530
Thanks: 574

The pricing of Scenesse is the biggest barrier to a rapid rollout in America. PW believes the drug is under-priced, this unfortunate miscalculation, coupled with his welded on no discounts policy is preventing entry-level marketing opportunities. The stock shorter is not the problem he sees the real problem for what it is; slow sales. I would hope a few questions at the AGM are aimed at getting PW to elaborate on his steadfast refusal to follow the industry norm of offering price discounts. I’m not to saying PW is not an expert in all things including marketing, far more likely I just don't get it.

Said 'Thanks' for this post: joules mm1  
post Posted: Nov 14 2019, 10:27 AM
  Quote Post

Posts: 536
Thanks: 1137

Called Ameritrade and voted on at least some of my holdings.

Sharing a screen shot but largely the same as Punk's screenshot. Called the 888 number and stated what I wanted and 10 minutes later it was done. (Voted No to compensation package, yes to everything else). Note, if you are going to try to vote your CLVLY shares, they said the gurantee deadline finished that morning, and now is just a best effort vote.
Attached thumbnail(s)
Attached Image


Said 'Thanks' for this post: PunkassDerm  San Diego  
post Posted: Nov 14 2019, 06:09 AM
  Quote Post

Posts: 770
Thanks: 1641

post Posted: Nov 14 2019, 05:14 AM
  Quote Post

Posts: 536
Thanks: 1137

CUV down 3% yesterday on another shorting attack, but CLVLY up 2% today. This is the first I recall seeing this. This means arbitrage opportunity for BNY to buy CUV shares and convert to CLVLY shares... putting further pressure on the shorters.

Said 'Thanks' for this post: LevelHeaded2000  Kalaz  
post Posted: Nov 14 2019, 01:47 AM
  Quote Post

Posts: 30
Thanks: 81

From Clinuvel's Facebook page:

"CLINUVEL has created a knowledge hub to deliver key information on erythropoietic protoporphyria (EPP), photomedicine, photoprotection, and the Company. Join us to learn, download and share helpful material.

Follow the link to discover more:"

Link to Facebook Post

Said 'Thanks' for this post: hibchibbler  LevelHeaded2000  PortugueseMan  gerritbakker57  royco  Texas T  
post Posted: Nov 14 2019, 12:39 AM
  Quote Post

Posts: 17
Thanks: 14

In Reply To: ignoramus's post @ Nov 12 2019, 05:17 PM

You´re wright Iggy!
But it´s not Clinuvel!
There are other forces, who works.

The last word Wisdom ever has to say:
He only earns his Freedom and Existence,
Who’s forced to win them freshly every day.

Said 'Thanks' for this post: San Diego  

Featured Stock Stories

the near future
post Posted: Nov 13 2019, 03:05 PM
  Quote Post

Posts: 533
Thanks: 473

In Reply To: Billy Boots's post @ Nov 13 2019, 03:01 PM

Yes very obvious
It seems it will continue for a while
Until the AGM or may be end of the year
And tomorrow is the drop to around 29 before starts going up again

Said 'Thanks' for this post: Billy Boots  
Billy Boots
post Posted: Nov 13 2019, 03:01 PM
  Quote Post

Posts: 304
Thanks: 234

Look at the Buys and Sells, they're at it again.SO BLOODY OBVIOUS

post Posted: Nov 13 2019, 11:19 AM
  Quote Post

Posts: 77
Thanks: 204

In Reply To: PunkassDerm's post @ Nov 13 2019, 09:07 AM

Thanks PADerm. TD Ameritrade gave me the runaround today. Your emails from them are helpful.

Said 'Thanks' for this post: PunkassDerm  
post Posted: Nov 13 2019, 10:10 AM
  Quote Post

Posts: 1,623
Thanks: 1857

Melbourne-based Avita making a big move.

AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, including optimizing support for clinical trials and development projects, as well as the Company’s continued U.S. commercial growth strategy.

Said 'Thanks' for this post: Kalaz  Lisa0825  

5076 Pages (Click to Jump) V  « < 303 304 305 306 307 308 309 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.